Differential effects of putative lipoxygenase inhibitors on arachidonic acid metabolism in cell-free and intact cell preparations
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The effects of nordihydroguairetic acid (NDGA), 3-amino-1-trifluoromethyl-)-phenyl-2-pyrazoline (BW755c), eicostatetraynoic acid (ETYA), phenidone, quercetin, and indomethacin (INDO) on the synthesis of 15-hydroxyeicosatatetraenoic acid (15-HETE) from soybean 15-lipoxygenase, leukotriene B4 (LTB4 from 5-lipoxygenase, and prostaglandin E2 (PGE2 from cyclooxygenase enzymes of rat neutrophils and mouse peritoneal macrophages were investigated. All of the drugs caused a dose-related inhibition of increased oxygen consumption by soybean 15-lipoxygenase in the presence of arachidonic acid and the rank order of potency was phenidone ≥ BW755c > ETYA > quercetin > NDGA > indomethacin. The reduction in oxygen consumption correlated with a reduction of 15-HETE formation as identified by high-performance liquid chromatography. Apart from indomethacin, these drugs were also effective against the rat neutrophil 5-lipoxygenase, although the rank order of potency did not correlate with that obtained with soybean 15-lipoxygenase. Furthermore, in both A23187-activated rat neutrophils and zymosan-activated mouse peritoneal macrophages the synthesis of prostaglandins was inhibited by all of these drugs. In the neutrophils, the rank order of potency was INDO > ETYA > BW755c > quercetin > NDGA > phenidone, whereas in mouse peritoneal macrophages, the order was INDO > ETYA > BW755c > NDGA > quercetin > phenidone. These results suggest that putative lipoxygenase inhibitors exhibit both qualitative and quantitative differences in their effects on both lipoxygenases and cyclooxygenases.
- Lewis, R. A., andK. F. Austen. 1981. Mediation of local homeostasis and inflammation by leukotrienes and their mast cell-dependent compounds.Nature 293:103–108.
- Samuelsson, B., S. Hammarstrom, R. C. Murphy, andP. Borgeat. 1980. Leukotrienes and slow reacting substances (SRS-A).Allergy 35:375–381.
- Piper, P. J., M. N. Samhoun, J. R., Tippins, T. J. Williams, M. A. Palmer, andM. J. Peck. 1981. Pharmacological studies on pure SRS-A and synthetic leukotrienes C4 and D4. In SRS-A and Leukotrienes. P. J. Piper, editor. Research Studies Press, John Wiley, New York, 81–89.
- Drazen, J. M., K. F. Austen, andR. A. Lewis. 1980. Comparative airway and vascular activities of leukotriene C-l and D in vivo and in vitro.Proc. Natl. Acad. Sci. U.S.A. 77:4354–4358.
- Michelassi, F., L. Landa, R. D. Hill, E. Lowenstein, W. D. Watkins, A. J. Petkan, andH. M. Zapol. 1982. Leukotriene D4: A potent cocoronary artery vascoconstrictor associated with impaired ventricular contraction.Science 217:841–843.
- Hanna, C. J., M. K. Bach, P. D. Pare, andR. R. Schellenberg. 1981. Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro.Nature 290:343–344.
- Hedqvist, P., S. E. Dahlen, L. Gustafsson, S. Hammarstrom, andB. Samuelsson. 1980. Biological profile of leukotrienes C4 and D4.Acta Physiol. Scand. 110:331–333.
- Holroyde, M. D., R. E. Altounyan, M. Cole, M. Dixon, andE. V. Elliott. 1981. Bronchoconstriction produced in man by leukotriene C and D.Lancet 2:17–18.
- Dahlen, S. E., P. Hedqvist, S. Hammarstrom, andB. Samuelsson. 1980. Leukotrienes and potent constrictors of human bronchi.Nature 288:484–486.
- Morom, Z., J. H. Shelhamer, M. K. Bach, D. R. Morton, andM. Kaliner. 1982. Slowreacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro.Am. Rev. Respir. Dis. 126:449–451.
- Williams, T. J., andP. J. Piper. 1980. The action of chemically pure SRS-A on the microcirculation in vivo.Prostaglandins 19:779–789.
- Dahlen, S. E., J. Bjork, P. Hedqvist, K. E. Arfors, S. Hammarstrom, J. A. Lindgren, andB. Samuelsson. 1981. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: In vivo effects with relevance to the acute inflammatory response.Proc. Natl. Acad. Sci. U.S.A. 78:3887–3891.
- Ford-Hutchinson, A. W., M. A. Bray, M. V. Doig, M. E. Shipley, andM. J. H. Smith, 1980. Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.Nature 286:264–265.
- Goetzl, E. J., A. R. Brash, A. J. Tauber, J. A. Oates, andW. C. Hubbard, 1980. Modulation of human neutrophil function by monohydroxy-eicosatetraenoic acids.Immunology 39:491–501.
- Stenson, W. F., andC. W. Parker, 1980. Monohydroxyeicosatetraenoic acids (HETEs) induce degranulation of human neutrophils.J. Immunol. 124:2100–2103.
- Klickstein, L. B., Shapleigh, C., andGoetzl, E. J., 1980. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis.J. Clin. Invest. 66:1166–1170.
- Yen, S. S., andH. G. Morris, 1981. An imbalance in arachidonic acid metabolism in asthma.Biochem. Biophys. Res. Commun. 103:774–779.
- Hamberg, M., 1976. On the formation of thromboxane B2 and 12L-hydroxy-5, 8, 10, 14-eicostetraenoic acid (12–20:4) in tissues from the guinea pig.Biochim. Biophys. Acta 431:651–654.
- Armour, C. L., J. M. Hughes, J. P. Seale, andD. M. Temple, 1981. Effect of lipoxygenase inhibitors on release of slow-reacting substances from human lung.Eur. J. Pharmacol. 72:93–96.
- Harvey, J., andD. J. Osborne. 1983. A rapid method for detecting inhibitors of both cyclooxygenase and lipoxygenase metabolites of arachidonic acid.J. Pharmacol. Methods 9:147–155.
- Higgs, G. A., R. J. Flower, andJ. R. Vane. 1979. A new approach to antiinflammatory drugs.Biochem. Pharmacol. 28:1959–1961.
- Radmark, O., C. Malmsten, andB. Samuelsson. 1980. The inhibitory effects BW755c on arachidonic acid metabolism in human polymorphonuclear leukocytes.FEBS Lett. 110:213–215.
- Hamberg, M., andB. Samuelsson. 1974. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets.Proc. Natl. Acad. Sci. U.S.A. 71:3400–3404.
- Blackwell, G. J., andR. J. Flower. 1978. 1-Phenyl-3-pyrazolidone: An inhibitor of cyclicoxygenase and lipoxygenase pathways in lung and platelets.Prostaglandins 16:417–425.
- Hope, W. C., A. F. Welton, C. F. Nagy, C. B. Bernardo, andJ. W. Coffey. 1983. In vitro inhibition of the biosynthesis of slow reacting substance of anaphylaxis (SRS-A) and lipoxygenase activity by quercetin.Biochem. Pharmacol. 32:367–371.
- Baumann, J., F. V. Bruchhausan, andG. Wurm. 1980. Flavanoids and related compounds as inhibitors of arachidonic acid peroxidation.Prostaglandins 20:727–739.
- Robak, J., andZ. Dumec. 1982. The influence and some 3-amino-2-pyrazoline derivatives on cyclooxygenase and lipoxidase activities.Biochem. Pharmacol. 31:1955–1959.
- Knippel, I., J. Baumann, F. Bruchhausen, andG. Wurm. 1981. Interactions of sulfhydryl agents and soybean lipoxygenase inhibitors.Biochem. Pharmacol. 30:1677–1684.
- Flower, R. J. 1974. Drugs which inhibit prostaglandin biosynthesis.Pharmacol. Rev. 26:33–66.
- Vanderhoek, J. Y., R. W. Bryant, andJ. M. Bailey. 1980. Inhibition of leukotriene biosynthesis by the leukocyte product, 15-hydroxy-5, 8, 11, 13-eicosatetraenoic acid.J. Biol. Chem. 255:10064–10066.
- Lanni, C., andE. L. Becker. 1983. Inhibition of neutrophil phospholipase A2 (PLA2 by bromophenylaculbromide (BPB), nordihydroguiaretic acid (NDGA), eicosatetraenoic acid (ETYA) and quercetin.Fed. Proc. 42:1906.
- Differential effects of putative lipoxygenase inhibitors on arachidonic acid metabolism in cell-free and intact cell preparations
Volume 8, Issue 2 , pp 143-155
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- Industry Sectors